Viral hepatitis.

Abstract

Developments over the last four years in our understanding of viral hepatitis are analyzed. The molecular structure of hepatitis A has been established, and vaccines for prevention are under development. The recognition of the replicative and integrated stages of hepatitis B infection has allowed more rational approaches to therapy. Vaccines are of proven value. Delta virus infection has assumed an important role world wide as a cause of serious and fulminant liver disease in hepatitis B carriers. The agents for non-A, non-B virus hepatitis have eluded identification. These are important causes of chronic liver disease particularly in recipients of blood transfusion.